The financing round was led by Cornerstone with backing from several early stage investors.
"Rising care costs, an overstretched social care system, and the demands of daily life can leave families feeling guilty and stretched thin as they think about their elderly loved ones. That’s why I’m thrilled to back George and Alex as they build Gladys, a managed social care platform that makes it easy to find and book trusted caregivers and companions. Their mission is close to my heart: giving families peace of mind and helping everyone grow old with dignity, in the home they cherish, for as long as possible."
The round was co-led by Oxford Science Enterprises and Cedars-Sinai to accelerate US expansion.
"We’ve spent the last two years proving that remote monitoring can transform neurological care. Clinicians are getting clearer insight without added workload, patients no longer face months of uncertainty between visits, and gain confidence that changes will be recognized rather than missed."
The grant from the US Advanced Research Projects Agency for Health will support the POSEIDON programme for early oncology intervention.
"The field of cancer screening needs a revolution, and POSEIDON stands ready to deliver. The program allows for a better future by creating broadly accessible, at-home tests that will accurately detect 30+ cancers as early as Stage I, when tumours are still small and the chances of survival are high,"
The seed round was led by Nexus Venture Partners with participation from athlete investment collective 4CAST.
"The medical tourism market holds immense untapped value, and The Medical Travel Company’s full-stack model is the key to unlocking it. Having founded one of India’s most successful consumer-tech stories, Sahil, Ankit and their team are uniquely positioned to build trust and capture this opportunity. India has long been a leading medical frontier, with world-class practitioners and cutting-edge technology; it’s about time this excellence is made globally accessible"
The financing round was led by IQ Capital to accelerate clinical trials for glioblastoma and other solid tumours.
"This significant investment accelerates our lead programme in glioblastoma and follow-on programme in colorectal cancer liver metastases through the clinic, advances our pipeline in liver and lung cancers, and further enhances our Odysseus platform. We are honoured to have the support of existing and new investors who share our mission to deliver breakthrough treatments and pursue cures for the thousands of patients and families facing devastating diagnoses each year."
